WATCHconviction 3published 2026-09-11

NRIM — Northrim BanCorp, Inc. · 2026-09-11 · Verdict: WATCH · Conviction 3

Price $26.05 (screen price, 2026-09-11 run; no live quote) · Mkt cap $579M · P/E 10.1x TTM adjusted · P/TBV 1.95x · ROTCE 21.1% annualised Q2'26 · TBVPS +23.1% y/y · ADV $3.1M (Financial-lane name: EV, EV/EBIT, FCF yield and net cash are not meaningful for a deposit-funded bank and are replaced above per the desk convention.) Sources read: 10-K filed 2026-03-06 (Items 1, 1A, 7), 10-Q filed 2026-07-31, DEF 14A 2026-04-14, 8-Ks 2026-07-23 (merger; Item 2.02 results), 2026-04-22, 2026-06-01, Form 4s to 2026-09-08. No call transcript exists: the transcript file is the Q2 press release (file header, content_type press_release).

Desk stats

1. What the business does

A $3.4B-asset Anchorage bank holding company, third largest in Alaska by deposits, with 21 branches and three segments: Community Banking; Home Mortgage Lending (Residential Mortgage LLC, which sells most originations and retains AHFC servicing); and Specialty Finance (Northrim Funding Services plus Sallyport Commercial Finance, acquired 31 October 2024, factoring receivables in the US, Canada and the UK) (10-K Item 1). Deposits are $2.92B, 76% business, 28% non-interest-bearing, average cost of interest-bearing deposits 1.71%. That franchise is the asset: it produced a 5.01% tax-equivalent margin in Q2 2026, and it exists because Alaska has few competing banks.

2. Why it might be mispriced, and the honest answer

There is no clean edge case. The screen anomaly is an artifact, and 1.95x tangible book for a 21% ROTCE bank is fair, not stolen. What is real but modest: the September split reset the quote from about $100 to $26, and this is a $580M, $3.1M-a-day name with one holder above 5% in the proxy (Dimensional, 6.1%). At 1.95x tangible book, a 10.5% cost of equity and 4% growth, the price implies a sustainable ROTCE near 16.7% against 21.1% delivered last quarter. The market has two defensible reasons for that discount: the margin is at a cycle high on an asset-sensitive book, and credit is turning. A discount is not a mispricing, so the verdict caps at WATCH.

3. Credit quality, margin and deposits

Credit is the thing to watch. Non-performing loans net of government guarantees went 0.35% of portfolio loans at 30 June 2025, to 0.60% at 31 March 2026, to 0.91% at 30 June 2026, and allowance coverage of them fell from 290% to 175% to 117% (8-K 2026-07-23 EX-99.1). Management attributes the Q2 jump mostly to one well-collateralised commercial real estate and commercial relationship (10-Q MD&A). Two offsets: net charge-offs were $111,000 in Q2 2026 and 0.08% of average loans in 2025, and net adversely classified loans fell to $33.4M from $35.8M a year ago. Concentrations are real: $767.6M of non-owner-occupied CRE (13% office, 12% hotels), 20% of the book in 28 relationships, $128.6M (5%) with direct Alaska oil and gas exposure, 39% uninsured deposits and 26% of deposits in 33 customers (10-K Item 1; 10-Q). The securities book is clean: accumulated unrealised AFS losses of $1.3M after tax, 2.5-year weighted average maturity, so there is no hidden capital hole.

4. Balance sheet and capital allocation

Tier 1 to risk-weighted assets 10.67% at year-end 2025; TCE/TA 8.82% at 30 June 2026. Holding-company debt is $60M of subordinated notes issued in Q4 2025 (Tier 2) plus $10M of trust preferred swapped to a fixed 3.72% (10-K Item 7; 10-Q). Split-adjusted share count has been roughly flat since 2022, and the company "did not repurchase any shares in the second quarter of 2026 and currently has no plans to repurchase shares this year" (8-K 2026-07-23). Dividend $0.64 in 2025, a 22% payout. Insiders and directors own 2.4% (DEF 14A). Form 4s show net selling of about $553,000: the Chief Banking Officer sold 13,488 shares on 31 July 2026, roughly half his holding; the Chief Credit Officer sold 4,000; the CFO sold 3,492 on 28 August. One director bought 1,200 at $26.20 on 8 September. The Chief Credit Officer selling while non-performing loans double is a datapoint, not a verdict, but it is not encouraging.

5. Management: said versus did

Stated strategy is "calculated, sustainable organic and inorganic market share growth" (10-K Item 1), and they have done both: Sallyport in 2024, then on 22 July 2026 an all-stock agreement to buy PBCO Financial (People's Bank of Commerce, Medford, Oregon, $776.6M assets, eleven branches) at 1.160 NRIM shares per PBCO share, about $167.3M, their first out-of-state expansion. Stated terms: 173.4% of tangible book, 15.9x 2027 earnings falling to 11.0x with cost savings, 24% cost saves ($6.3M fully phased in 2028), $14.4M one-time expense, a $7.5M credit mark (1.26% of PBCO loans), 2.5% TBV dilution with a sub-2.4-year earnback, and 3.5% ($0.10) EPS accretion in 2028 (8-K 2026-07-23 EX-99.2). Note the arithmetic: $0.10 equal to 3.5% implies management models standalone 2028 EPS of only about $2.86, barely above the trailing $2.55. Fairly priced with modest accretion, not a bargain.

6. Valuation

Bear ($20, 25%): the Fed cuts, the asset-sensitive book reprices, tax-equivalent margin falls toward 4.4%, the CRE relationship and follow-on push provisions to 60bp of loans, normalised EPS drops to about $2.20 and the multiple derates to 8.5x. Base ($34, 55%): the merger closes Q4 2026 or Q1 2027; tangible book of $13.34 takes the 2.5% dilution then compounds near 13% on a 22% payout to about $17.25 by end-2028; at an unchanged 1.95x that is $33.6 plus about $1.47 of dividends, and the same answer comes from management's implied $2.96 pro forma 2028 EPS at 11x. Bull ($41.50, 20%): saves land at 24%, the $100M securities repositioning out of a 1.58% yield adds about $3.4M pre-tax, margin holds near 5%, 2028 EPS $3.20 at 12.5x. Probability-weighted $32.0, about 23% above $26.05 over roughly two and a quarter years, near 10% a year before dividends. Reverse DCF: at $26.05 the price implies a sustainable return on tangible common equity of about 16.7%, so the market already assumes roughly a fifth of current profitability goes away.

7. Catalysts and timeline

Form S-4 and joint proxy; both shareholder votes; regulatory approvals; close Q4 2026 or early Q1 2027, system conversion Q4 2027. Q3 2026 results in late October are the first read on whether the Q2 non-performing jump was one relationship or a trend.

8. Risks and pre-registered kill criteria

  1. Non-performing loans net of government guarantees exceed 1.25% of portfolio loans, or allowance coverage of them falls below 90%, in two consecutive quarters.
  2. Tax-equivalent net interest margin falls below 4.50% in two consecutive quarters.
  3. The PBCO merger is terminated, or realised tangible book dilution at close exceeds 5% against the 2.5% guided.
  4. Net charge-offs exceed 0.35% of average loans over any trailing twelve months, against 0.08% in 2025.

9. Verdict and summary

WATCH, conviction 3. Northrim is a genuinely good small bank the screen flagged for the wrong reason: the eye-catching "-70% tangible book per share" is nothing but a four-for-one stock split in September 2025 that the prior-year XBRL share count never adjusted, and the 9x P/E leans on a $14.5M one-time gain from selling a wealth-management affiliate. Strip both out and you have a $3.4B Alaska commercial bank earning 21% on tangible common equity with a 5.01% margin, 28% non-interest-bearing deposits, a clean securities book and tangible book up 23% in a year, at 10x normalised earnings and 1.95x tangible book. That price already implies profitability falling to about a 16.7% ROTCE, so the discount is not absurd, and two things justify it: the margin is at a cycle high on an asset-sensitive balance sheet, and non-performing loans tripled to 0.91% of loans in four quarters while allowance coverage fell from 290% to 117%, with the Chief Credit Officer and CFO both selling stock into it. The pending all-stock purchase of PBCO adds 21% more shares for 3.5% accretion in 2028 and is fairly, not cheaply, priced. A fine business at a fair price with a credit question open: wait for the Q3 print to say whether the bad loans are one relationship or the start of a cycle.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.

Source markdown: 2026-09-11_NRIM.md · how these notes are built · every verdict tracked since publication.

Research and education only. Nothing here is investment advice or a recommendation to buy or sell any security. No price targets are recommendations; positions and sizing are the reader's decision. Past performance does not predict future results.